Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
239.62
+2.67 (1.13%)
Jul 22, 2026, 4:00 PM EDT - Market closed
Axsome Therapeutics Employees
Axsome Therapeutics had 1,220 employees as of March 31, 2026. The number of employees increased by 508 or 71.35% compared to the same quarter last year.
Employees
1,220
Change
508
Growth
71.35%
Revenue / Employee
$580,521
Profits / Employee
-$154,347
Market Cap
12.33B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 1,220 | 508 | 71.35% |
| Dec 31, 2025 | 925 | 242 | 35.43% |
| Sep 30, 2025 | 816 | 209 | 34.43% |
| Jun 30, 2025 | 846 | 257 | 43.63% |
| Mar 31, 2025 | 712 | 143 | 25.13% |
| Dec 31, 2024 | 683 | 138 | 25.32% |
| Sep 30, 2024 | 607 | 105 | 20.92% |
| Jun 30, 2024 | 589 | 167 | 39.57% |
| Mar 31, 2024 | 569 | 176 | 44.78% |
| Dec 31, 2023 | 545 | 162 | 42.30% |
| Sep 30, 2023 | 502 | 150 | 42.61% |
| Jun 30, 2023 | 422 | 224 | 113.13% |
| Mar 31, 2023 | 393 | 277 | 238.79% |
| Dec 31, 2022 | 383 | 275 | 254.63% |
| Sep 30, 2022 | 352 | 246 | 232.08% |
| Jun 30, 2022 | 198 | 105 | 112.90% |
| Mar 31, 2022 | 116 | 46 | 65.71% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Exelixis | 1,077 |
| Madrigal Pharmaceuticals | 915 |
| Corcept Therapeutics | 730 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
| Krystal Biotech | 295 |
AXSM News
- 2 days ago - Axsome Therapeutics initiated with an Outperform at BMO Capital - TheFly
- 2 days ago - Axsome Therapeutics initiated with an Outperform at BMO Capital - TheFly
- 7 days ago - Axsome Therapeutics announces FDA acceptance of AXS-12 NDA - TheFly
- 7 days ago - Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy - GlobeNewsWire
- 8 days ago - Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10 - GlobeNewsWire
- 15 days ago - Axsome Therapeutics price target raised to $304 from $302 at RBC Capital - TheFly
- 15 days ago - Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD) - GlobeNewsWire
- 21 days ago - Why Axsome Stock Has Doubled In Nine Months - Forbes